Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs
Archives of Microbiology · 2026-07 · 208 (7)
DOI: 10.1007/s00203-026-04846-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, online erschienen am 25.04.2026. Verfasst von Kritika Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Endopeptidases, Bacteriophages, Anti-Bacterial Agents, Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 130 Literaturangaben.
Abstract (Originalsprache)
Due to the global rise of antimicrobial resistance (AMR), conventional antibiotics are becoming increasingly ineffective in treating bacterial infections. Innovative approaches are needed to understand bacterial resistance mechanisms and fully preserve human health. Endolysins, peptidoglycan hydrolases derived from bacteriophages, offer a novel approach to tackling AMR by targeting bacterial cell walls. Endolysins exhibit remarkable specificity for bacterial species, strains, and antibiotic-resistant variants. Their mechanism of action involves degrading the peptidoglycan layer in bacterial cell walls, leading to rapid cell lysis. This unique mode of action reduces the likelihood of cross-resistance with existing antibiotics, making endolysins a potential therapeutic option. This review provides a comprehensive overview of endolysin biology, including their structure, classification, and mechanisms of action, and emphasizes their potential as novel antibacterial agents. A unique contribution of this review is the integrated analysis of recent advances in endolysin protein engineering and nanotechnology, highlighting how these approaches have expanded endolysins’ functional scope by improving stability, pharmacokinetics, delivery efficiency, and antibiofilm activity, and by enhancing activity against Gram-negative bacteria. Importantly, this review also identifies research gaps and translational challenges, including susceptibility to serum proteases, short circulatory half-life, immunogenicity, delivery barriers posed by Gram-negative outer membranes, manufacturing scalability, and regulatory considerations. By examining the strengths and challenges of endolysin therapies, this review outlines future research directions and translational strategies, positioning endolysins as alternative therapeutic agents within emerging antimicrobial frameworks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. drneelampgi@yahoo.com.
Zitieren
APA
Sharma, K., Chaudhary, N., Kaur, H., & Taneja, N. (2026). Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs. Archives of Microbiology, 208(7). https://doi.org/10.1007/s00203-026-04846-1
Vancouver
Sharma K, Chaudhary N, Kaur H, Taneja N. Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs. Archives of Microbiology. 2026;208(7). doi:10.1007/s00203-026-04846-1
BibTeX
@article{Sharma2026,
author = {Sharma, Kritika and Chaudhary, Naveen and Kaur, Harpreet and Taneja, Neelam},
title = {Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs},
journal = {Archives of Microbiology},
year = {2026},
volume = {208},
number = {7},
doi = {10.1007/s00203-026-04846-1}
}
EUVIMED